Treats hypertension. ANDA 202519, held by Aurobindo Pharma Ltd. Hydrochlorothiazide; Valsartan.
As of Nov 16, 2026, ANDA 202519 (Valsartan And Hydrochlorothiazide), held by Aurobindo Pharma Ltd, was first approved by FDA on Mar 21, 2013, with 5 approved supplements and 0 published complete response letters.
Valsartan and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets, USP.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 21, 2013 | Original application | Approved | None posted |
| Valsartan And Hydrochlorothiazide12.5MG;80MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
| Valsartan And Hydrochlorothiazide12.5MG;160MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
| Valsartan And Hydrochlorothiazide12.5MG;320MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
| Valsartan And Hydrochlorothiazide25MG;160MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
| Valsartan And Hydrochlorothiazide25MG;320MG · tablet;oral | Hydrochlorothiazide; Valsartan | Rx |
| Apr 4, 2022 | Supplement 15Labeling · Standard review | Approved | None posted |
| Aug 16, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 16, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 16, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 16, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 21, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters